Medical Advocates
HIV Infection/Disease
  Dyslipidemia
 		  
General Reports
Clinical Management
 

 
Adipose Tissue  Main Page   Main New/Newsworthy Home Page  
Last Update: January 26, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader.

General Reports
       
       Videos
 
 
Dyslipidemia and HIV
Heidi Crane, MD, MPH

        Journal Papers, Abstracts, and Commentaries

 
Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.
Egaña-Gorroño L, Martínez E,  et al
AIDS. 2012 Dec 19..
 Abstract

The distribution of Apolipoprotein E gene polymorphism and their influences in dyslipidemias in HIV-1 infections.
Suwalak T, Srisawasdi P, Puangpetch A, et al
 Jpn J Infect Dis. 2014 Nov 25.
 Abstract

FULL-TEXT ARTICLE
 Erectile Dysfunction Among HIV Patients Undergoing Highly Active Antiretroviral Therapy: Dyslipidemia as a Main Risk Factor.
 Romero-Velez G, Lisker-Cervantes A, Villeda-Sandoval CI,  et al
 Sex Med. 2014 Apr;2(1):24-30
 Paper

FULL-TEXT ARTICLE
Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study.
Abebe M, Kinde S, Belay G,  et al
 BMC Res Notes. 2014 Jun 21;7:380. 
Paper

Prevalence, treatment, and control of dyslipidemia and hypertension in 4278 HIV outpatients.
Myerson M, Poltavskiy E, Armstrong EJ,
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):370-7.
 Abstract

FULL-TEXT ARTICLE
Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART.
Lazzaretti RK, Gasparotto AS, Sassi MG, et al
 ScientificWorldJournal. 2013 Sep 26;2013:608415
 Paper

FULL-TEXT ARTICLE
Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.
Muhammad S, Sani MU, Okeahialam BN.
 Ann Afr Med. 2013 Jan-Mar;12(1):24-8
 Paper

Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011.
Tripathi A, Jerrell JM, Liese AD,  et al
 Metab Syndr Relat Disord. 2013 Dec;11(6):417-26
 Abstract

FULL-TEXT PDF ARTICLE
 Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study.
Tadewos A, Addis Z, Ambachew H, Banerjee S.
 AIDS Res Ther. 2012 Oct 25;9(1):31.
 Paper

FULL-TEXT ARTICLE
 Dyslipidaemia in HIV-1-infected patients receiving protease inhibitors after initial treatment with first-line-based non-nucleoside reverse transcriptase inhibitors: a cross-sectional study.
Pefura Yone EW, Kengne AP,  Ashuntantang G,  et al
BMJ Open. 2012 Aug 8;2(
 Paper

FULL-TEXT ARTICLE
HIV and HAART-Associated Dyslipidemia.
Feeney ER, Mallon PW.
 Open Cardiovasc Med J. 2011;5:49-63.
Paper

The Effect of polymorphisms in candidate genes on the Long-Term Risk of Lipodystrophy
and Dyslipidemia in HIV-infected Caucasians Starting Antiretroviral Therapy.
Marzocchetti A, Schwarz J, DI Giambenedetto S,   et al 
AIDS Res Hum Retroviruses. 2011 May 20.
Abstract

FULL-TEXT ARTICLE
 Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
Nery MW, Martelli CM, Turchi MD.
Braz J Infect Dis. 2011 Apr;15(2):151-5.
 Paper

Dyslipidemia related to antiretroviral therapy.
EstradaV, Portilla J.
AIDS Rev. 2011 Jan-Mar;13(1):49-56.
 Abstract

High Molecular Weight Form of Adiponectin in Antiretroviral Drug-induced
Dyslipidemia in HIV-Infected Japanese Individuals Based on in vivo and
in vitro Analyses.
Minami R, Yamamoto M, Takahama S, Ando H, et al
Intern Med. 2009;48(20):1799-875
 Abstract

Association of APOC3 Polymorphisms with Both Dyslipidemia and Lipoatrophy in
HAART-Receiving Patients.
Bonnet E, Bernard J, Fauvel J, Massip P
AIDS Res Hum Retroviruses. 2008 Feb 1
Abstract
 
Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by
the APOA5-1131T->C Gene Variation.
 Guardiola M, Ferre R, Salazar J, et al
Clin Chem. 2006 Aug 3;
Abstract
 
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV
infection and dyslipidemia.
Reeds DN, Yarasheski KE, Fontana L
Am J Physiol Endocrinol Metab. 2005 Aug 23
 Abstract
 
Dyslipidaemia and cardiovascular risk in HIV infection.
 Kulasekaram R, Peters BS, Wierzbicki AS. 
Curr Med Res Opin. 2005 Nov;21(11):1717-25
 Abstract
 
Lipodystrophy and Dyslipidemia Among Patients Taking First-Line, World Health Organization-
Recommended Highly Active Antiretroviral Therapy Regimens in Western India.
Pujari SN, Dravid A, Naik E, et al 
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):199-202
 Abstract
 
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy
(HAART) on cardiovascular risk and life expectancy
 Grover SA, Coupal L, Gilmore N, Mukherjee J.
 Am J Cardiol. 2005 Mar 1;9
 Abstract
 
Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome
Activity and Glucose Transport by HIV Protease Inhibitors.
Parker RA, Flint OP, Mulvey R, et al
 Mol Pharmacol. 2005 Mar 8;
 Abstract
 
Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV
lipodystrophy: a model of ‘systemic steatosis’
Balasubramanyam A, Sekhar RV, Jahoor F, et al  
Curr Opin Lipidol. 2004 Feb;15(1):59-67.
 Abstract
 
Cardiovascular Implications of HIV-associated Dyslipidemic Lipodystrophy.
Sekhar RV, Jahoor F, Pownall HJ, et al 
Curr Atheroscler Rep. 2004 May;6(3):173-9.
 Abstract

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L, Manfredi R, Chiodo F.et al 
J Antimicrob Chemother. 2003 Nov 25
Abstract

Alterations in lipid kinetics in men with HIV-dyslipidemia.
Reeds DN, Mittendorfer B, Patterson BW
 Am J Physiol Endocrinol Metab 2003 May 13;
 Abstract

  

        Conference Reports, Abstracts, and Posters

 
Incidence of dyslipidemia and glucose impairments among HIV patients after HAART: the experience of a Brazilian outpatient clinic
L. Ferreira da Silva Pinto Neto, M.D.C. Milanez, R. Ribeiro-Rodrigues, et al
(XIX International AIDS Conference)
 Abstract

Dyslipemia and Hyperinsulinemia in HIV Patients on HAART  
 (41 ICAAC)
Abstract

  

Clinical Management
       
        Journal Papers, Abstracts, and Commentaries
 
 
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Grandi AM, Nicolini E, Rizzi L, et al
J Int AIDS Soc. 2014 Aug 21;17:19004. .
 Abstract

Management of dyslipidemia in patients with human immunodeficiency virus.
Shalit P.
 Rev Cardiovasc Med. 2014;15 Suppl 1:S38-46.
Abstract

Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction
Pedersen KK, Pedersen M, Trøseid M,  et al
 J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):425-33
 Abstract

Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT.
 Postgrad Med. 2012 Jan;124(1):31-40..
 Abstract

Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug
leflunomide in a PPAR-γ-dependent manner.
 Mencarelli A, Francisci D, Renga B,  et al
Antivir Ther. 2012 Jan 25.
Abstract

FULL-TEXT PDF ARTICLE
 Dyslipidemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the
Spanish VACH cohort.
 Estrada V, Geijo P, Fuentes-Ferrer M, et al  
BMC Womens Health. 2011 Aug 4;11(1):36
Paper

Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia
and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of
"Heart Positive," a Randomized, Controlled Trial.
Balasubramanyam A, Coraza I, Smith EO,  et al
J Clin Endocrinol Metab. 2011 May 11
 Abstract

Dyslipidemia and lipid management in HIV-infected patients.
Lo J.
Curr Opin Endocrinol Diabetes Obes. 2011 Feb 3
 Abstract

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Singh S, Willig JH, Mugavero MJ,M., et al
 Clin Infect Dis. 2010 Dec 28.
 Abstract

Treatment of dyslipidemia in HIV-infected patients.
Sekhar RV, Balasubramanyam A.
Expert Opin Pharmacother. 2010 May 20
 Abstract

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable
background antiretroviral therapy: ACTG 5206.
 Tungsiripat M, Kitch D, Glesby MJ, et al
AIDS. 2010 May 21
 Abstract

Evaluation and Pharmacologic Management of the HIV-Infected Patient With Dyslipidemia.
Hardwicke RL, Lewis ST, Grimes RM.
J Assoc Nurses AIDS Care. 2010 Mar 18.
 Abstract

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors:
a randomized trial.
Aslangul E, Assoumou L, Bittar R, et al
AIDS. 2009 Oct 15
 Abstract

HIV-associated dyslipidaemia: pathogenesis and treatment.
Oh J, Hegele RA 
Lancet Infect Dis. 2007 Dec;7(12):787-96.
 Abstract
 
Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids.
Metroka CE, Truong P, Gotto AM Jr.  
AIDS Read. 2007 Jul;17(7):362-4, 367-73.
 Abstract
 
Management of Dyslipidemia and Other Cardiovascular Risk Factors in HIV-Infected Patients:
Case-based Review.
Aberg JA.
Top HIV Med. 2006 Oct-Nov;14(4):134-9.
Abstract
 
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected
patients with poor response to statins.
Negredo E, Molto J, Puig J, et al  
AIDS. 2006 Nov 14;20(17):2159-2164.
 Abstract
 
Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia.
 Soler A, Deig E, Guil J, Rodriguez-Martin M, Guelar A, Pedrol E.
Med Clin (Barc). 2006 Jul 15;127(7):250-2
 Abstract

Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
 Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. 
Med Sci Sports Exerc. 2006 Mar;38(3):411-7.
 Abstract
 
  Strategies for management and treatment of dyslipidemia in HIV/AIDS.
 Sax PE. 
AIDS Care. 2006 Feb;18(2):149-157
 Abstract
 
  Management of dyslipidemia in patients with complicated metabolic syndrome.
 Davidson MH.  
 Am J Cardiol. 2005 Aug 22;96(4A):22-5.
 Abstract
 
  Treatment of dyslipidaemia in HIV-infected persons.
 Manuel O, Thiebaut R, Darioli R, Tarr PE.
 Expert Opin Pharmacother. 2005 Aug;6(10):1619-45.
Abstract
 
  The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with
lipodystrophy.
 Shah M, Tierney K, Adams-Huet B, et al
HIV Med. 2005 Jul;6(4):291-8.
 Abstract
   
  Lipid lowering effects of statins and fibrates in the management of HIV
dyslipidemias associated ith antiretroviral therapy in HIV clinical practice.
 Visnegarwala F, Maldonado M, Sajja P, et al 
J Infect. 2004 Nov;49(4):283-90.
Abstract
 
  Effects of pravastatin on lipoproteins and endothelial function in patients receiving
human immunodeficiency virus protease inhibitors.
 Stein JH, Merwood MA, Bellehumeur JL ,et al.
Am Heart J. 2004 Apr;147(4):713.
 Abstract
 
  Reduction of fat accumulation and lipid disorders by individualized light aerobic
training in human immunodeficiency virus infected patients with lipodystrophy
and/or dyslipidemia.
 Thoni GJ, Fedou C, Brun JF,  et al
 Diabetes Metab 2002 Nov;28(5):397-404
 Abstract
   
  Evaluation and Management of Dyslipidemia in Patients with HIV Infection.
Green ML
J Gen Intern Med 2002 Oct;17(10):797-810
 Abstract
   
  A pilot study of the safety and efficacy of cholestin in treating HIV-related
dyslipidemia.
 Keithley JK, Swanson B, Sha BE, et al.
Nutrition 2002 Feb;18(2):201-204
 Abstract
 
        Conference Reports, Abstracts, and Posters
 
 
Effect of interventions to improve dyslipidaemia
 M vd Valk, N Friis-Møller, C Sabin, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Rosuvastatin in the treatment of dyslipidaemia in HIV patients
 S Das, M Boothby, C Stradling , et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 

Adipose Tissue  Main Page   Main New/Newsworthy Home Page  

Dyslipidemia